ESRD impairs nonrenal clearance of fexofenadine but not midazolam

Journal of the American Society of Nephrology

Volumn 20, Issue 10, 2009, Pages 2269-2276

  Nolin, Thomas D ^a   Frye, Reginald F ^b   Le, Phuong ^c   Sadr, Hooman ^d   Naud, Judith ^e   Leblond, Francois A ^e   Pichette, Vincent ^e   Himmelfarb, Jonathan ^f  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

^c Maine Medical Center Research Institute   (United States)

^d Tidewater Kidney Specialists   (United States)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

^f UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA HYDROXYMIDAZOLAM; CYTOCHROME P450; CYTOCHROME P450 3A; FEXOFENADINE; MIDAZOLAM; 1-HYDROXYMETHYLMIDAZOLAM; DRUG DERIVATIVE; GLYCOPROTEIN P; ORGANIC ANION TRANSPORTER; TERFENADINE;

ADULT; AGED; ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG HALF LIFE; DRUG TRANSPORT; FEMALE; HUMAN; INTESTINE CELL; KIDNEY FAILURE; LIVER CELL; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; UREMIA; ANIMAL; CHRONIC KIDNEY FAILURE; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PROSPECTIVE STUDY; SPRAGUE DAWLEY RAT; UREA NITROGEN BLOOD LEVEL;

ADULT; AGED; ANIMALS; BLOOD UREA NITROGEN; CYTOCHROME P-450 CYP3A; ENTEROCYTES; FEMALE; HEPATOCYTES; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; METABOLIC CLEARANCE RATE; MIDAZOLAM; MIDDLE AGED; ORGANIC ANION TRANSPORTERS; P-GLYCOPROTEIN; PROSPECTIVE STUDIES; RATS; RATS, SPRAGUE-DAWLEY; TERFENADINE;

EID: 70349902844     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2009010082     Document Type: Article

References (44)

1. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS: Prevalence of chronic kidney disease in the United States. JAMA 298: 2038-2047, 2007 (Pubitemid 350074801)
2. Manley HJ, Cannella CA, Bailie GR, St. Peter WL: Medication-related problems in ambulatory hemodialysis patients: A pooled analysis. Am J Kidney Dis 46: 669-680, 2005
3. Bates DW, Miller EB, Cullen DJ, Burdick L, Williams L, Laird N, Petersen LA, Small SD, Sweitzer BJ, Vander Vliet M, Leape LL: Patient risk factors for adverse drug events in hospitalized patients. ADE Prevention Study Group. Arch Intern Med 159: 2553-2560, 1999
4. Evans RS, Lloyd JF, Stoddard GJ, Nebeker JR, Samore MH: Risk factors for adverse drug events: A 10-year analysis. Ann Pharmacother 39: 1161-1168, 2005 (Pubitemid 40943163)
5. Nolin TD, Naud J, Leblond FA, Pichette V: Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin Pharmacol Ther 83: 898-903, 2008 (Pubitemid 351704931)
6. Sun H, Frassetto L, Benet LZ: Effects of renal failure on drug transport and metabolism. Pharmacol Ther 109: 1-11, 2006 (Pubitemid 41740811)
7. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130: 461-470, 1999
8. Lemma GL, Wang Z, Hamman MA, Zaheer NA, Gorski JC, Hall SD: The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates. Clin Pharmacol Ther 79: 218-230, 2006 (Pubitemid 43297014)
9. Robertson SM, Davey RT, Voell J, Formentini E, Alfaro RM, Penzak SR: Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects. Curr Med Res Opin 24: 591-599, 2008 (Pubitemid 351294409)
10. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, Wilkinson GR: Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 59: 491-502, 1996 (Pubitemid 26193889)
11. Masica AL, Mayo G, Wilkinson GR: In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam. Clin Pharmacol Ther 76: 341-349, 2004 (Pubitemid 39313124)
12. Meyer TW, Hostetter TH: Uremia. N Engl J Med 357: 1316-1325, 2007
13. Lee JI, Chaves-Gnecco D, Amico JA, Kroboth PD, Wilson JW, Frye RF: Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. Clin Pharmacol Ther 72: 718-728, 2002 (Pubitemid 36021011)
14. Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J, Schuetz EG, Thummel KE: Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 62: 162-172, 2002 (Pubitemid 34680528)
15. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ, Wilkinson GR: Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res 16: 408-414, 1999 (Pubitemid 29162099)
16. Vinik HR, Reves JG, Greenblatt DJ, Abernethy DR, Smith LR: The pharmacokinetics of midazolam in chronic renal failure patients. Anesthesiology 59: 390-394, 1983 (Pubitemid 14227510)
17. Leblond FA, Guevin C, Demers C, Pellerin I, Gascon-Barre M, Pichette V: Downregulation of hepatic cytochrome P450 in chronic renal failure. J Am Soc Nephrol 12: 326-332, 2001 (Pubitemid 32116374)
18. Leblond FA, Petrucci M, Dube P, Bernier G, Bonnardeaux A, Pichette V: Downregulation of intestinal cytochrome P450 in chronic renal failure. J Am Soc Nephrol 13: 1579-1585, 2002 (Pubitemid 34579247)
19. Guevin C, Michaud J, Naud J, Leblond FA, Pichette V: Down-regulation of hepatic cytochrome P450 in chronic renal failure: role of uremic mediators. Br J Pharmacol 137: 1039-1046, 2002 (Pubitemid 35440744)
20. Michaud J, Dube P, Naud J, Leblond FA, Desbiens K, Bonnardeaux A, Pichette V: Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450. Br J Pharmacol 144: 1067-1077, 2005 (Pubitemid 40593005)
21. Dowling TC, Briglia AE, Fink JC, Hanes DS, Light PD, Stackiewicz L, Karyekar CS, Eddington ND, Weir MR, Henrich WL: Characterization of hepatic cytochrome P4503A activity in patients with end-stage renal disease. Clin Pharmacol Ther 73: 427-434, 2003 (Pubitemid 36549827)
22. Nolin TD, Appiah K, Kendrick SA, Le P, McMonagle E, Himmelfarb J: Hemodialysis acutely improves hepatic CYP3A4 metabolic activity. J Am Soc Nephrol 17: 2363-2367, 2006 (Pubitemid 44300952)
23. Watkins PB: Noninvasive tests of CYP3A enzymes. Pharmacogenetics 4: 171-184, 1994
24. Kurnik D, Wood AJ, Wilkinson GR: The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity. Clin Pharmacol Ther 80: 228-234, 2006 (Pubitemid 44301092)
25. Frassetto LA, Poon S, Tsourounis C, Valera C, Benet LZ: Effects of uptake and efflux transporter inhibition on erythromycin breath test results. Clin Pharmacol Ther 81: 828-832, 2007 (Pubitemid 46788293)
26. Lam JL, Okochi H, Huang Y, Benet LZ: In vitro and in vivo correlation of hepatic transporter effects on erythromycin metabolism: Characterizing the importance of transporter-enzyme interplay. Drug Metab Dispos 34: 1336-1344, 2006 (Pubitemid 44079874)
27. Lau YY, Huang Y, Frassetto L, Benet LZ: Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther 81: 194-204, 2007 (Pubitemid 46174816)
28. Frassetto LA, Sun H, Huang Y, Benet LZ: Uremic toxins decrease hepatic clearance but not oral bioavailability of erythromycin in patients with end stage renal disease [Abstract]. J Am Soc Nephrol 19: 929A, 2008
29. Matsushima S, Maeda K, Ishiguro N, Igarashi T, Sugiyama Y: Investigation of the inhibitory effects of various drugs on the hepatic uptake of fexofenadine in humans. Drug Metab Dispos 36: 663-669, 2008
30. Tahara H, Kusuhara H, Fuse E, Sugiyama Y: P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion. Drug Metab Dispos 33: 963-968, 2005 (Pubitemid 41002778)
31. Yi SY, Hong KS, Lim HS, Chung JY, Oh DS, Kim JR, Jung HR, Cho JY, Yu KS, Jang IJ, Shin SG: A variant 2677A allele of the MDR1 gene affects fexofenadine disposition. Clin Pharmacol Ther 76: 418-427, 2004
32. Niemi M, Kivisto KT, Hofmann U, Schwab M, Eichelbaum M, Fromm MF: Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). Br J Clin Pharmacol 59: 602-604, 2005 (Pubitemid 40632253)
33. Wandel C, Witte JS, Hall JM, Stein CM, Wood AJ, Wilkinson GR: CYP3A activity in African American and European American men: Population differences and functional effect of the CYP3A4*1B5′-promoter region polymorphism. Clin Pharmacol Ther 68: 82-91, 2000 (Pubitemid 30609830)
34. Floyd MD, Gervasini G, Masica AL, Mayo G, George AL Jr, Bhat K, Kim RB, Wilkinson GR: Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics 13: 595-606, 2003 (Pubitemid 37311146)
35. Kharasch ED, Walker A, Isoherranen N, Hoffer C, Sheffels P, Thummel K, Whittington D, Ensign D: Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. Clin Pharmacol Ther 82: 410-426, 2007 (Pubitemid 47414348)
36. Drescher S, Schaeffeler E, Hitzl M, Hofmann U, Schwab M, Brinkmann U, Eichelbaum M, Fromm MF: MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol 53: 526-534, 2002 (Pubitemid 34527155)
37. Glaeser H, Bailey DG, Dresser GK, Gregor JC, Schwarz UI, McGrath JS, Jolicoeur E, Lee W, Leake BF, Tirona RG, Kim RB: Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther 81: 362-370, 2007 (Pubitemid 46364477)
38. Tian X, Zamek-Gliszczynski MJ, Li J, Bridges AS, Nezasa K, Patel NJ, Raub TJ, Brouwer KL: Multidrug resistance-associated protein 2 is primarily responsible for the biliary excretion of fexofenadine in mice. Drug Metab Dispos 36: 61-64, 2008
39. Tian X, Swift B, Zamek-Gliszczynski MJ, Belinsky MG, Kruh GD, Brouwer KL: Impact of basolateral multidrug resistance-associated protein (Mrp) 3 and Mrp4 on the hepatobiliary disposition of fexofenadine in perfused mouse livers. Drug Metab Dispos 36: 911-915, 2008 (Pubitemid 351574889)
40. Matsushima S, Maeda K, Hayashi H, Debori Y, Schinkel AH, Schuetz JD, Kusuhara H, Sugiyama Y: Involvement of multiple efflux transporters in hepatic disposition of fexofenadine. Mol Pharmacol 73: 1474-1483, 2008 (Pubitemid 351574837)
41. Naud J, Michaud J, Boisvert C, Desbiens K, Leblond FA, Mitchell A, Jones C, Bonnardeaux A, Pichette V: Down-regulation of intestinal drug transporters in chronic renal failure in rats. J Pharmacol Exp Ther 320: 978-985, 2007 (Pubitemid 46294060)
42. Naud J, Michaud J, Lebond FA, Lefrancois S, Bonnardeaux A, Pichette V: Effects of chronic renal failure on liver drug transporters. Drug Metab Dispos 36: 124-128, 2008
43. Russell T, Stoltz M, Weir S: Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers. Clin Pharmacol Ther 64: 612-621, 1998 (Pubitemid 29011381)
44. Faul F, Erdfelder E, Lang AG, Buchner A: G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 39: 175-191, 2007